Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s Laboratories Ltd. (BSE: 500124). The deal centers on Bio-Thera’s BAT2206, a biosimilar version of Stelara (ustekinumab), and BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab). Dr. Reddy’s will gain exclusive rights to commercialize these products in Southeast Asia, while Bio-Thera will continue to handle development, manufacturing, and supply. Financial details of the agreement were not disclosed.
Commercialization Rights and Responsibilities
Dr. Reddy’s has secured exclusive distribution and sales rights for BAT2206 and BAT2506 in Southeast Asian markets, including Cambodia, Indonesia, Malaysia, the Philippines, and Thailand. The company is responsible for regulatory filing and commercialization in these countries. Additionally, Dr. Reddy’s will hold exclusive commercialization rights for BAT2206 in the Colombian market.
Regulatory Status
BAT2206 is currently awaiting regulatory decisions in China, the US, and the European Union (EU), while BAT2506 is under review in China and the EU.-Fineline Info & Tech
Leave a Reply